IBDJournal & CC360

[IBDJournal & CC360 @IBDJournals]

IBD Innovate is around the corner. Gather with experts involved in the development of novel therapies, devices, and diagnostics for IBD. Register now: https://t.co/thqHMpIWaj #IBDInnovate26

Check out this video and hear from 2025 attendees: https://t.co/Ki2yVwa7bY

[IBDJournal & CC360 @IBDJournals]

#IBDInnovate26 is the only conference that brings together leaders from across the IBD R&D ecosystem. If you are an academic or industry researcher, investor, or funder looking to learn, share, and connect, we’ll see you there! Register now to save: https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

IBD Innovate is a platform to turn science into solutions.

Meet potential partners, explore co-development and funding opportunities, and support product-oriented research that addresses critical unmet needs for people living with IBD.

Register now: https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

For 10 years #CCCongress27 has created connections that build careers, strengthen practices & advance next-gen research & care. Join us for game-changing networking with leaders at the forefront of #IBD science & clinical strategy. ➡️ https://t.co/CwroaB1l1x @AmerGastroAssn

[GI Nutrition Foundation @GI_NutritionFdn]

Why do symptoms linger in #Crohnsdisease in remission❓

Recent findings from @IBDimmunology, @umfoodoc & colleagues found clues:

✅ Patients with quiescent Crohn's and persistent symptoms were enriched in sulfur-containing amino acid pathways

✅ Downstream mitochondrial function was also perturbed

✅ Patients with quiescent Crohn's and persistent symptoms shared similar microbial diversity, community structure, and metabolites with active Crohn's

✅ A dietary pattern that reduces the growth of sulfur-metabolizing gut microorganisms has shown potential benefits in adults with mild–moderately active ulcerative colitis by @Alice_APD et al. and might be considered also in some patients with Crohn's in remission:
🔸 Prioritize intake of fruits, vegetables and fiber (> 30g fiber/day)
🔸 Gluten is allowed
🔸 Moderate animal protein intake (1 g/kg)
🔸 ⬇️ meat intake
🔸 ⬇️ additives

💡 Despite normalization of inflammation, gut microbiome structure and functions can be altered in patients with Crohn's with persistent symptoms 👉 diet can help by preventing the bloom of microbes that feed on dietary sulfur

📚 Read the full research in @IBDJournals :

https://t.co/WMdCIL7Bck

[IBDJournal & CC360 @IBDJournals]

If you’re developing or investing in innovative products for IBD, IBD Innovate is designed for you. It is the only conference uniting the full IBD R&D ecosystem to learn, share, and connect around novel patient solutions. Secure your spot. #IBDInnovate26 https://t.co/PA52wfU4eW

[IBDJournal & CC360 @IBDJournals]

IBD Innovate brings together the full IBD R&D ecosystem—scientists, entrepreneurs, investors, & industry leaders—to accelerate the development of next-generation therapies, diagnostics, devices, & digital health solutions for IBD. Join us: https://t.co/thqHMpIWaj #IBDinnovate26

[IBDJournal & CC360 @IBDJournals]

“It’s a really important place where researchers & innovators come together to turn discoveries into treatments for patients.” IBD Innovate brings together scientists, founders, & investors advancing new products for Crohn’s disease & ulcerative colitis. https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

Now in its eighth year, IBD Innovate is the only conference that convenes industry leaders, academics, startups, investors and patients to advance the development of therapies, devices, and diagnostics for IBD. https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

Connect with colleagues & multidisciplinary leaders for 3 days of practical insights, breakthrough science & collaborative learning at #CCCongress27 Jan. 21-23. Early Bird rates end 9/16—REGISTER NOW & help shape the future of IBD research & clinical care. https://t.co/CwroaB1l1x

[IBDJournal & CC360 @IBDJournals]

Connect with colleagues & multidisciplinary leaders for 3 days of practical insights, breakthrough science & collaborative learning at #CCCongress27 in NOLA Jan. 21-23. Early Bird rates end 9/16—REGISTER NOW 🔗 https://t.co/CwroaB1l1x

[IBDJournal & CC360 @IBDJournals]

📣 Have new IBD research to share? Now’s the time!

Submit your abstract to the 2027 Crohn���s & Colitis Congress® & showcase your work alongside leading researchers & clinicians advancing IBD.

🗓️Deadline: September 23

Don’t miss out to share your science & help move IBD forward.

[Mohamed Eldesouki, MD @Eldesouki_mo]

🚨 See our new study in @IBDJournals on RSV risk in patients with active #IBD!

🦠 Active IBD was associated with higher risk of RSV infection compared with nonactive disease.

💊 The increased RSV risk persisted in active IBD regardless of systemic steroid use.

💉 Among RSV-vaccinated patients, infection rates were no longer higher in active IBD.

Read the article here:
🔗 https://t.co/HP6WsdXifF

Grateful to Dr @FarrayeIBD @JHashashMD, and @Alomari_MD for the guidance and mentorship!

Huge thanks to @YoussefBHafez & @DrAhmedSalem2 for your help and support!

[Budoor Alqinai @Budooralqinai]

Proud to share that our original cohort study "GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study" has been published in Inflammatory Bowel Diseases @IBDJournals ! @AmerGastroAssn @AmCollegeGastro @CrohnsColitisFn @GJenhadam @WVU_GI #ibd #inflammatoryboweldisease

"In this 1:1 matched cohort study of 300 patients with active ulcerative colitis, GLP-1 RA therapy was associated with significantly higher symptomatic remission rates at 12 weeks (66.7% vs 25.3%; adjusted OR 5.90) compared to matched controls, with benefits appearing early and independent of weight loss ."

https://t.co/M08jaQQrpn

[IBDJournal & CC360 @IBDJournals]

Join us for the 2026 Virtual IBD Pro: APP Education Conference on November 7!

Designed for advanced practice providers caring for people with IBD, this one-day virtual conference features expert-led sessions.

Register here:
https://t.co/dt1dKjNu1W

[IBDJournal & CC360 @IBDJournals]

What happens at IBD Innovate? Join IBD scientists, industry leaders from pharma and biotech, and stage investors to learn, connect, and explore opportunities on the latest innovations in therapies, devices, and diagnostics for IBD in development. https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

🎉 Congratulations to our 2026 Editorial Fellows!

We're proud to welcome the newest cohort to the Crohn's & Colitis Foundation's Editorial Fellowship Program, working across our two scientific journals — Inflammatory Bowel Diseases®️ and Crohn's & Colitis 360.

[IBDJournal & CC360 @IBDJournals]

⚜️Join us in NOLA for #CCCongress2027 on Jan. 21-23!⚜️ Discover the power of multidisciplinary collaboration & connect with the clinicians, scientists & integrated healthcare professionals revolutionizing #IBD care. Early Bird discounts expire on 9/16: https://t.co/hLUvYhohmK

[IBDJournal & CC360 @IBDJournals]

IBD Innovate offers a look at the IBD pipeline from early-stage concepts to near-market products. Connect with teams translating research into therapies, diagnostics, and devices that improve life for people with IBD. https://t.co/thqHMpIWaj

[IBDJournal & CC360 @IBDJournals]

Now in its eighth year, IBD Innovate showcases the latest innovations in therapies, diagnostics, devices, and digital health solutions for inflammatory bowel disease. Register now to save. #IBDInnovate26